Zhejiang Hisun Pharmaceutical Co Ltd (600267):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Zhejiang Hisun Pharmaceutical Co Ltd (600267) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7619
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥68,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥102,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Zhejiang Hisun Pharmaceutical Co Ltd (Hisun) is a pharmaceutical company that manufactures and commercializes active pharmaceutical ingredients, antibiotics and anticancer drugs. The company offers active pharmaceutical ingredients and bulk drugs used in anti-neoplastics. It offers products in the areas of cardiovascular, anti-infection, anti-parasite, endocrine control, immunoinhibitors and anti-depression. Hisun offers active pharmaceutical ingredient such as acarbose, adenosine, bicalutamide, irbesartan, mevastatin, pitavastatin calcium, cladribine, cyclophosphamaide, rosuvastatin calcium, meropenem, imipenem, daptomycin, tobramycin and others. Hisun also offers contract manufacturing services. The company operates through its research and development facilities located in Shanghai and Beijing. Hisun is headquartered in Taizhou, Zhejiang, China.

Zhejiang Hisun Pharmaceutical Co Ltd (600267) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Zhejiang Hisun Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
Infectious Disease Research Institute Enters into Agreement with Zhejiang Hisun Pharma 14
GeneriCo Enters into Distribution Agreement with Zhejiang Hisun Pharmaceutical 15
Celsion Enters into Agreement with Zhejiang Hisun Pharma 16
Zhejiang Hisun Pharma Enters into Memorandum of Understanding (MoU) with Sanofi 17
Zhejiang Hisun Pharma to Enter Co-Development Agreement with Ambrx 18
Catalent Pharma Enters Into An Agreement With Zhejiang Hisun Pharma To Develop Biosimilars 19
Celsion Expands Technology Development Agreement With Zhejiang Hisun Pharma 20
Celsion Enters Into Technology Development Agreement With Zhejiang Hisun Pharma For ThermoDox 21
Pfizer Forms Joint Venture With Zhejiang Hisun Pharma For Generic Medicines 23
Zhejiang Hisun Pharma to Form Joint Venture With Beijing-Based Technology Company 24
Enzon Pharma Enters Into Co-Development Agreement With Zhejiang Hisun Pharma 25
Licensing Agreements 26
Zhejiang Hisun Pharma Enters into Licensing Agreement with Nascent Biotech 26
Zhejiang Hisun Pharma Enters into Licensing Agreement with Eli Lilly for Capreomycin 27
Enzon Pharma Enters Into Licensing Agreement With Zhejiang Hisun Pharma For PEG-SN38 28
Zhejiang Hisun Pharma Enters into Licensing Agreement with Fujifilm 29
Equity Offering 30
Zhejiang Hisun Pharma Plans to Raise up to USD143.8 Million in Private Placement of Shares 30
Zhejiang Hisun Pharma Receives Regulatory Approval for Private Placement of Shares 31
Debt Offering 32
Zhejiang Hisun Pharma Raises USD307.6 Million in Public Offering of Bonds 32
Zhejiang Hisun Pharma Prices Private Placement of Bonds for USD184 Million 33
Zhejiang Hisun Pharma Announces Private Placement Of Notes For Up To US$327 Million 34
Zhejiang Hisun Pharma Announces Public Offering Of Bonds 35
Acquisition 36
Zhejiang Hisun Pharma to Acquire 68% Stake in China Based Pharma Company for USD24.5 Million 36
Zhejiang Hisun Pharma Plans to Divest Stake in Sagent Pharma 37
Zhejiang Hisun Pharma to Acquire 15% Stake in Zhejiang-Based Pharma Company for USD12 Million 38
Zhejiang Hisun Pharma Acquires Respirics, Respiratory Drug Developer 39
Zhejiang Hisun Pharmaceutical Co Ltd – Key Competitors 40
Zhejiang Hisun Pharmaceutical Co Ltd – Key Employees 41
Zhejiang Hisun Pharmaceutical Co Ltd – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Joint Venture 42
Recent Developments 43
Other Significant Developments 43
Jul 20, 2017: HISUN’s first intelligent FDF production line is put operation on July 20th 2015 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zhejiang Hisun Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Zhejiang Hisun Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Infectious Disease Research Institute Enters into Agreement with Zhejiang Hisun Pharma 14
GeneriCo Enters into Distribution Agreement with Zhejiang Hisun Pharmaceutical 15
Celsion Enters into Agreement with Zhejiang Hisun Pharma 16
Zhejiang Hisun Pharma Enters into Memorandum of Understanding (MoU) with Sanofi 17
Zhejiang Hisun Pharma to Enter Co-Development Agreement with Ambrx 18
Catalent Pharma Enters Into An Agreement With Zhejiang Hisun Pharma To Develop Biosimilars 19
Celsion Expands Technology Development Agreement With Zhejiang Hisun Pharma 20
Celsion Enters Into Technology Development Agreement With Zhejiang Hisun Pharma For ThermoDox 21
Pfizer Forms Joint Venture With Zhejiang Hisun Pharma For Generic Medicines 23
Zhejiang Hisun Pharma to Form Joint Venture With Beijing-Based Technology Company 24
Enzon Pharma Enters Into Co-Development Agreement With Zhejiang Hisun Pharma 25
Zhejiang Hisun Pharma Enters into Licensing Agreement with Nascent Biotech 26
Zhejiang Hisun Pharma Enters into Licensing Agreement with Eli Lilly for Capreomycin 27
Enzon Pharma Enters Into Licensing Agreement With Zhejiang Hisun Pharma For PEG-SN38 28
Zhejiang Hisun Pharma Enters into Licensing Agreement with Fujifilm 29
Zhejiang Hisun Pharma Plans to Raise up to USD143.8 Million in Private Placement of Shares 30
Zhejiang Hisun Pharma Receives Regulatory Approval for Private Placement of Shares 31
Zhejiang Hisun Pharma Raises USD307.6 Million in Public Offering of Bonds 32
Zhejiang Hisun Pharma Prices Private Placement of Bonds for USD184 Million 33
Zhejiang Hisun Pharma Announces Private Placement Of Notes For Up To US$327 Million 34
Zhejiang Hisun Pharma Announces Public Offering Of Bonds 35
Zhejiang Hisun Pharma to Acquire 68% Stake in China Based Pharma Company for USD24.5 Million 36
Zhejiang Hisun Pharma Plans to Divest Stake in Sagent Pharma 37
Zhejiang Hisun Pharma to Acquire 15% Stake in Zhejiang-Based Pharma Company for USD12 Million 38
Zhejiang Hisun Pharma Acquires Respirics, Respiratory Drug Developer 39
Zhejiang Hisun Pharmaceutical Co Ltd, Key Competitors 40
Zhejiang Hisun Pharmaceutical Co Ltd, Key Employees 41
Zhejiang Hisun Pharmaceutical Co Ltd, Joint Venture 42

List of Figures
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Zhejiang Hisun Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Zhejiang Hisun Pharmaceutical Co Ltd (600267):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CeQur SA:医療機器:M&Aディール及び事業提携情報
    Summary CeQur SA (CeQur) is a medical device company that develops and commercializes insulin delivery systems. The company offers product PAQ, a wearable insulin delivery device, which delivers both basal and bolus doses. Its PAQ product consist two components such as insulin reservoir and messenge …
  • American CryoStem Corp (CRYO):企業の財務・戦略的SWOT分析
    Summary American CryoStem Corp (American CryoStem), formerly Advanced Wound Technologies-MidAtlantic LLC is a manufacturer, developer, and marketer of life-enhancing and stem cell technologies. The company offers products such as adipose derived stem cells, tissue collection and transportation produ …
  • Newron Pharmaceuticals SpA (NWRN):製薬・医療:M&Aディール及び事業提携情報
    Summary Newron Pharmaceuticals SpA (Newron) is a research-based biopharmaceutical company which focuses on the discovery, development and commercialization of novel therapeutic drugs for the treatment of central nervous system disorders and pain. The company’s marketed product, Xadago (safinamide), …
  • Aeris Resources Limited:企業の戦略・SWOT・財務分析
    Aeris Resources Limited - Strategy, SWOT and Corporate Finance Report Summary Aeris Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Twitter, Inc.:企業のM&A・事業提携・投資動向
    Twitter, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Twitter, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • ViaCord LLC:企業の戦略的SWOT分析
    ViaCord LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Panhandle Oil and Gas Inc (PHX):石油・ガス:M&Aディール及び事業提携情報
    Summary Panhandle Oil and Gas Inc (Panhandle) sells oil, natural gas liquid (NGL) and natural gas produced from non-operated assets through working interests, royalty interests and both in producing oil and natural gas wells and those in the process of being drilled or completed. The company operate …
  • James Fisher and Sons Plc (FSJ):石油・ガス:M&Aディール及び事業提携情報
    Summary James Fisher and Sons Plc (James Fisher) is a service provider for global marine industry and a specialist supplier of engineering services to the energy industry. The company provides comprehensive services such as design and engineering; inspection and monitoring; lifting and handling; mar …
  • Gammon Construction Ltd:企業の戦略的SWOT分析
    Gammon Construction Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Starkey Hearing Technologies Inc:企業の戦略的SWOT分析
    Starkey Hearing Technologies Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Trilogy Health Services LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Trilogy Health Services LLC (Trilogy) is a healthcare service provider that offers senior living and long-term healthcare services. The center offers services such as independent living, assisted living, skilled nursing, memory care, rehabilitation, adult day service, respite care, home heal …
  • Canadian Tire Corp Ltd (CTC.A):企業の財務・戦略的SWOT分析
    Canadian Tire Corp Ltd (CTC.A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Enbridge Inc (ENB):企業の財務・戦略的SWOT分析
    Enbridge Inc (ENB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • MyoKardia Inc (MYOK):製薬・医療:M&Aディール及び事業提携情報
    Summary MyoKardia Inc (MyoKardia) is a clinical stage biopharmaceutical company. The company utilizes precision medicine platform to develop therapies for rare cardiovascular diseases including heritable cardiomyopathies. The company's pipeline products include therapeutic programs for the treatment …
  • Tata Communications Limited:企業の戦略・SWOT・財務分析
    Tata Communications Limited - Strategy, SWOT and Corporate Finance Report Summary Tata Communications Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Viavi Solutions Inc:企業の戦略・SWOT・財務分析
    Viavi Solutions Inc - Strategy, SWOT and Corporate Finance Report Summary Viavi Solutions Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Deutsche Apotheker- und Arztebank:企業の戦略・SWOT・財務分析
    Deutsche Apotheker- und Arztebank - Strategy, SWOT and Corporate Finance Report Summary Deutsche Apotheker- und Arztebank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Ora Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Ora Inc (Ora) is an ophthalmic contract research organization that provides clinical research and drug development services. The organization offers pre-clinical research, animal toxicology studies, and compounds identification and procurement services. It offers clinical study project manag …
  • Modiin Energy Limited Partnership (MDIN.L):石油・ガス:M&Aディール及び事業提携情報
    Summary Modiin Energy Limited Partnership (Modiin Energy) is an oil and gas company that offers crude oil exploration programs. The company operates in the exploration and development of oil and natural gas properties. It owns and operates five assets such as Shimshon, Daniel east, Daniel west, Grap …
  • CSL Limited:企業のM&A・事業提携・投資動向
    CSL Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CSL Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆